Sarepta Unveils New Real-World Data on Duchenne Therapy at NMSG 2026
Event summary
- Sarepta will present seven posters at the 27th Annual Neuromuscular Study Group Scientific Meeting, including first results from the Phase 4 ENDURE Study on delandistrogene moxeparvovec for Duchenne muscular dystrophy.
- Data includes real-world safety and efficacy insights, particularly in patients receiving prophylactic immunosuppression with sirolimus.
- Presentations cover clinical validation of micro-dystrophin expression, treatment delays, and safety analyses in postmarketing settings.
- Sarepta's portfolio also includes interim findings from Phase 1/2 studies on SRP-1003 for Myotonic Dystrophy Type 1 and SRP-1001 for FSHD1.
The big picture
Sarepta's presentation of real-world data at NMSG 2026 underscores the growing importance of postmarketing evidence in validating gene therapies. The focus on delandistrogene moxeparvovec's safety and efficacy in diverse patient settings aligns with broader industry trends toward personalized medicine and long-term outcomes tracking. The company's expanding portfolio in neuromuscular diseases positions it as a key player in precision genetic medicine, though competition and regulatory hurdles remain significant.
What we're watching
- Therapy Efficacy
- How the real-world performance of delandistrogene moxeparvovec compares to clinical trial results, particularly in broader patient populations.
- Regulatory Dynamics
- Whether the new data will influence FDA decisions on expanded indications or labeling changes for ELEVIDYS.
- Pipeline Progress
- The pace at which Sarepta advances its siRNA therapies (SRP-1003 and SRP-1001) through Phase 1/2 studies.
Related topics
